Metabolic HealthNew Dual Agonist Survodutide Cuts Body Weight Nearly 10% in Obese Adults with Type 2 Diabetes
Survodutide, an investigational drug that activates both the glucagon receptor and the GLP-1 receptor, was tested in 752 adults with obesity and type 2 diabetes in the phase 3 SYNCHRONIZE-2 trial. Over 76 weeks, participants receiving the higher 6.0 mg weekly dose lost an average of 9.8% of body weight versus 3.9% with placebo. More than 64% of those on the higher dose achieved at least 5% weight loss. Blood sugar control also improved, with hemoglobin A1c dropping roughly 0.8 to 0.9 percentage points on active treatment. Gastrointestinal side effects were common but generally mild and temporary. The findings suggest survodutide may offer a meaningful new option for managing the overlapping epidemics of obesity and type 2 diabetes, two conditions that accelerate biological aging and cardiovascular disease risk.
